Lakefront Biotherapeutics NV current report, Q2 FY2021

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of April 2021. The filing, dated April 9, 2021, serves to incorporate by reference a press release issued on April 8, 2021 (Exhibit 99.1). The registrant is a foreign private issuer incorporated in Belgium.

Financial Metrics

The provided filing text does not contain specific financial data. It acts as a conduit for a press release and does not report revenue, profit, cash flow, margins, debt, or liquidity figures within the body of this document.

Material Changes

The filing text does not detail specific material changes or comparative period analysis. It references a press release (Exhibit 99.1) which likely contains the material event, but the content of that release is not included in the provided text.

Guidance, Outlook, and Risks

No guidance, outlook, management commentary, or risk factors are explicitly stated in the provided text. The document notes that quotes from Mr. Andrew Dickinson and Mr. Bart Filius are contained in Exhibit 99.1 but does not reproduce them here.

Key Facts for Investor Verification

  • Verify the content of Exhibit 99.1 (Press Release dated April 8, 2021) to understand the specific material event triggering this filing.
  • Confirm the registrant is Galapagos NV, as the metadata company name "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing text.
  • Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing offerings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.